News
11-12-2009, 06:20 AM
An analysis conducted by the Finnish Breast Cancer Group and published in The Lancet Oncology shows women at intermediate to high-risk of early breast cancer recurrence who received capecitabine as part of their chemotherapy regimen had a 34% reduction in the risk of the disease returning or death, compared with those taking the chemotherapy combination regimen without capecitabine.
More... (http://www.medicalnewstoday.com/articles/170676.php)
More... (http://www.medicalnewstoday.com/articles/170676.php)